Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MultISyn

Financiado

Cerrado

Multimodal Imaging of rare Synucleinopathies

Despite remarkable progress in the understanding of the molecular pathogenesis of neurodegenerative diseases (NDD), no causative or disease-modifying treatment is currently available. Aggregation of misfolded proteins are thought... ver más

30/09/2018

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-09-30 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

0.00€ | Lider

PMOD

N.D. | Participante

BIOMEDICAL RESEARCH FOUNDATI...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SUPD Sizing Up PD Cavity enhanced Characterisation of Single Bio... 290K€ Cerrado

Biomarkers for PD Validation of diagnostic and prognostic biomarkers for Parki... 71K€ Cerrado

CTQ2014-59544-P UNA PERSPECTIVA ATOMISTICA DE LA DETECCION, TOXICIDAD Y AGRE... 143K€ Cerrado

ABETAALPHASYNTAU Insight into the synergistic interactions between A amyloid... 100K€ Cerrado

TEC2012-34306 DIAGNOSTICO MEDIANTE MODELOS ESTADISTICOS E INTELIGENTES (DI... 81K€ Cerrado

RTC-2016-5186-1 Control objetivo del deterioro cognitivo mediante análisis d... 494K€ Cerrado

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite remarkable progress in the understanding of the molecular pathogenesis of neurodegenerative diseases (NDD), no causative or disease-modifying treatment is currently available. Aggregation of misfolded proteins are thought to play a crucial role in the pathogenesis, but attempts to exploit this knowledge for novel treatments have not been successful. Also, pathogenetically relevant biomarkers of protein aggregation are lacking. In order to overcome this critical road-block, we have assembled an interdisciplinary consortium, consisting of world-leading experts in structural biology and ligand development, multimodal neuroimaging, animal models and clinical trials to develop a novel imaging system for combined simultaneous molecular and functional imaging (PET-MRI/fMRI) for two rare diseases caused by excessive accumulation of misfolded alpha-synuclein (αSYN), multiple systems atrophy (MSA) and parkinsonism caused by mutations in the alpha-synuclein gene (SNCA), which will serve as proof-of-principle models for the more common and heterogeneous NDD. With this technology we will pioneer the monitoring of protein aggregation as a biomarker for therapeutic effects in the framework of individualized causative treatment. The central aspects of the work-flow including ligand design, software development and drug trials will be driven by three highly specialized SMEs, while translation to animal models and clinical use will be implemented by top academic centers. The groundbreaking progress will include: 1. Establish a multimodal imaging algorithm based on a new PET tracer and embracing structural and functional MRI methods to yield an αSYN specific tool 2. Test this multimodal, molecular neuroimaging algorithm in animal models with regard to its potential for diagnosis, mirroring the natural disease course and response to therapy 3. Translate the algorithm including the therapeutic modality (i.e. immunotherapy with PD01, NCT01568099) to the clinical setting.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores